Efficacy and safety of mirabegron for the treatment of low compliance bladder resulting from sacral/infrasacral lesions: A prospective study.
acontractile detrusor
low compliance
mirabegron
neurogenic bladder
urodynamics
Journal
International journal of urology : official journal of the Japanese Urological Association
ISSN: 1442-2042
Titre abrégé: Int J Urol
Pays: Australia
ID NLM: 9440237
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
29
10
2019
accepted:
08
03
2020
pubmed:
20
4
2020
medline:
28
4
2021
entrez:
20
4
2020
Statut:
ppublish
Résumé
To assess the efficacy and safety of mirabegron in patients with sacral/infrasacral lesions who have an acontractile detrusor and develop a low compliance bladder. This prospective study included adult patients with acontractile detrusor as a result of sacral/infrasacral lesions who develop a low compliance bladder (compliance <20 mL/cmH A total of 17 patients were included. After 6 weeks of mirabegron therapy, the number of patients reporting leakage in between clean intermittent catheterization reduced from seven to two (P = 0.02), the end filling pressures reduced from 41.4 to 15.1 cmH Mirabegron reduces end filling pressure, improves compliance and is safe in patients with a low compliance bladder resulting from a sacral/infrasacral lesion.
Substances chimiques
Acetanilides
0
Thiazoles
0
mirabegron
MVR3JL3B2V
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
552-558Informations de copyright
© 2020 The Japanese Urological Association.
Références
Hackler RH, Hall MK, Zampieri TA. Bladder hypocompliance in the spinal cord injury population. J. Urol. 1989; 141: 1390-3.
Park WH, Kim HG, Heo YC, So JG, Lim YS, Shim HB. Urodynamic study in spinal cord injured patients: classification and analysis of high risk parameters for upper tract deterioration. Korean J. Urol. 2000; 41: 92-8.
Wyndaele JJ, Gammie A, Bruschini H et al. Bladder compliance what it does represent: can we measure it, and is it clinically relevant? Neurourol. Urodyn. 2011; 30: 714-22.
Park WH. Management of low compliant bladder in spinal cord injured patients. LUTS 2010; 2: 61-70.
McGuire EJ, Woodside JR, Borden TA, Weiss RM. Prognostic value of urodynamic testing in myelodysplastic patients 1981. J. Urol. 2002; 167: 1049-53.
Madhuvrata P, Singh M, Hasafa Z, Abdel-Fattah M. Anticholinergic drugs for adult neurogenic detrusor overactivity: a systematic review and meta-analysis. Eur. Urol. 2012; 62: 816-30.
Krebs J, Pannek J. Effects of solifenacin in patients with neurogenic detrusor overactivity as a result of spinal cord lesion. Spinal Cord 2013; 51: 306-9.
Tijnagel MJ, Scheepe JR, Blok BF. Real life persistence rate with antimuscarinic treatment in patients with idiopathic or neurogenic overactive bladder: a prospective cohort study with solifenacin. BMC Urol. 2017; 17: 30.
Wöllner J, Pannek J. Initial experience with the treatment of neurogenic detrusor overactivity with a new β-3 agonist (mirabegron) in patients with spinal cord injury. Spinal Cord 2016; 54: 78-82.
Rosier PFWM, Schaefer W, Lose G, Goldman HB, Guralnick M, Eustice S. International Continence Society Good Urodynamic Practices and Terms 2016: urodynamics, uroflowmetry, cystometry, and pressure-flow study. Neurourol. Urodyn. 2017; 36: 1243-60.
Krhut J, Borovička V, Bílková K et al. Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity-Prospective, randomized, double-blind, placebo, controlled study. Neurourol. Urodyn. 2018; 37: 2226-33.
Welk B, Hickling D, McKibbon M, Radomski S, Ethans K. A pilot randomized-controlled trial of the urodynamic efficacy of mirabegron for patients with neurogenic lower urinary tract dysfunction. Neurourol. Urodyn. 2018; 37: 2810-7.
Watanabe M, Yamanishi T, Honda M, Sakakibara R, Uchiyama T, Yoshida K. Efficacy of extended-release tolterodine for the treatment of neurogenic detrusor overactivity and/or low-compliance bladder. Int. J. Urol. 2010; 17: 931-6.
Kelleher C, Hakimi Z, Zur R et al. Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis. Eur. Urol. 2018; 74: 324-33.
Madersbacher H, Murtz G, Stohrer M. Neurogenic deterusor activity in adults: a review on efficacy, tolerability and safety of oral antimuscarinics. Spinal Cord 2013; 51: 432-41.